Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Johnson & Johnson

Johnson & Johnson
Regional / Research

J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks

October 28, 2026October 26, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its Crohn’s disease treatment Tremfya sustained or improved fistula remission through 48 weeks in a Phase 3 clinical trial, …

J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks Read More

Johnson & Johnson
Regional

Johnson & Johnson Reports Three-Year Crohn’s Drug Results

October 22, 2026October 22, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 clinical trial results showing sustained remission in patients receiving its Crohn’s disease treatment Tremfya for three years, …

Johnson & Johnson Reports Three-Year Crohn’s Drug Results Read More
Johnson & Johnson
Regional / Research

Johnson & Johnson Reports Sustained Psoriasis Drug Response

October 17, 2026October 15, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that more than 70% of patients receiving its oral psoriasis treatment ICOTYDE maintained clear or almost clear skin through two …

Johnson & Johnson Reports Sustained Psoriasis Drug Response Read More

Johnson & Johnson
Research

Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years

October 11, 2026October 10, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its oral psoriasis treatment ICOTYDE (icotrokinra) maintained skin clearance through 112 weeks in a Phase 3 clinical study, providing …

Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years Read More
Johnson & Johnson
Regional / Research

J&J’s IMAAVY Maintains Gains in Two-Year Adolescent Study

October 7, 2026October 5, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that adolescents with generalized myasthenia gravis maintained improvements in daily function and muscle strength through two years of IMAAVY treatment, …

J&J’s IMAAVY Maintains Gains in Two-Year Adolescent Study Read More

Johnson & Johnson
Regional

TREMFYA Meets Key Goals in Psoriatic Arthritis Study

October 1, 2026September 29, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson’s TREMFYA met the primary and major secondary endpoints in a Phase 4 trial of adults with psoriatic arthritis and axial involvement, showing improvements …

TREMFYA Meets Key Goals in Psoriatic Arthritis Study Read More
Johnson & Johnson
Regional

FDA Clears J&J’s IMAAVY as First Drug for Rare Blood Disease

September 2, 2026August 31, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) secured U.S. Food and Drug Administration approval for IMAAVY to treat warm autoimmune hemolytic anemia in patients 12 and older who …

FDA Clears J&J’s IMAAVY as First Drug for Rare Blood Disease Read More

Federal Trade Commission
National

FTC Backs Antitrust Suit Challenging J&J’s Stelara Monopoly

June 29, 2026June 28, 2026 - by Maryann Pugh

WASHINGTON, D.C. — The Federal Trade Commission has urged a federal appeals court to preserve an antitrust lawsuit accusing Johnson & Johnson of unlawfully maintaining its monopoly over the blockbuster …

FTC Backs Antitrust Suit Challenging J&J’s Stelara Monopoly Read More
Johnson & Johnson
Regional

FDA Expands TREMFYA Label to Include Joint Damage Data in Psoriatic Arthritis

June 7, 2026June 6, 2026 - by Timothy Alexander

HORSHAM, PA — The U.S. Food and Drug Administration has approved a label expansion for Johnson & Johnson’s (NYSE: JNJ) TREMFYA, allowing the company to market clinical evidence showing the …

FDA Expands TREMFYA Label to Include Joint Damage Data in Psoriatic Arthritis Read More
Johnson & Johnson
Regional

FDA Grants Priority Review to J&J sBLA for IMAAVY in wAIHA

May 6, 2026May 5, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has granted Priority Review to its supplemental Biologics License Application for IMAAVY (nipocalimab-aahu) to …

FDA Grants Priority Review to J&J sBLA for IMAAVY in wAIHA Read More

Posts pagination

1 2 … 4 Next

Trending News

  • Parkesburg Woman Arrested on Strangulation Charges

  • Tredyffrin/Easttown Plan Would Shift Elementary Boundaries

  • What Went Wrong at 7 Chester County Restaurants?

  • Camp Saginaw Withdraws New London Township Cell Tower Plan

  • Chadds Ford Art Museum Adds Outdoor Ice Rink for the Holidays

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Police news

Parkesburg Woman Arrested on Strangulation Charges

November 21, 2026November 20, 2026

Court News

Coatesville Woman Pleads Guilty to Voting Illegally Twice

November 20, 2026November 19, 2026

acw woman report

Pennsylvania Report Calls for Paid Leave, Workplace Reforms

November 20, 2026November 19, 2026

Copyright © 2026 MyChesCo.